The report details the company's efforts environmental, social, and governance areas.
Merck released its 2021/2022 Environmental, Social, and Governance (ESG) Progress Report, highlighting the company’s performance across four areas: access to health, employees, environmental sustainability, and ethics and values.
The report highlights several achievements in the ESG field from the past year. In the access to health category, the company noted that it committed 91.5 million doses of its HPV vaccines to Gavi-supported countries through 2025. Due to the expansion of manufacturing facilities, the company plans to double the supply of the vaccine in the coming years.
The report noted that Merck achieved greater-than 99% pay equity between male and female employees in 2021. This standard also occurred among diverse employees in equivalent positions, and this achievement is included in the employee section of the ESG report.
The report also notes that in the environmental sustainability section, Merck plans to achieve carbon neutrality by 2025. The company has already reduced greenhouse gas emissions in 2021 by 9% from a 2019 baseline. In the area of ethics and values, Merck notes that it has maintained 100% compliance with regulatory requirements for active incident monitoring, risk/harm analysis, and on-time notification of data breaches.
Merck’s full progress report can be read here.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.